Browse > Article
http://dx.doi.org/10.3857/jkstro.2009.27.3.133

Retrospective Analysis of Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer  

Lee, Jong-Hoon (Departments of Radiation Oncology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
Kim, Sung-Hwan (Departments of Radiation Oncology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
Kim, Su-Zy (Departments of Radiation Oncology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
Lee, Joo-Hwan (Departments of Radiation Oncology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
Kim, Hoon-Kyo (Departments of Medical Oncology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
Shim, Byoung-Yong (Departments of Medical Oncology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine)
Publication Information
Radiation Oncology Journal / v.27, no.3, 2009 , pp. 133-139 More about this Journal
Abstract
Purpose: This study was designed to analyze the outcome and toxicity of thoracic radiation therapy (TRT) and chemotherapy for patients who suffer with limited-stage small-cell lung cancer (LS-SCLC). Materials and Methods: We retrospectively studied 35 patients with LS-SCLC. TRT was administered once daily (1.8 to 2 Gy per fraction) and it was directed to the primary tumor for a total 50 to 66 Gy in 6 to 7 weeks. The patients received four cycles of etoposide plus cisplatin. TRT was begun on day 1 of the first cycle of chemotherapy in the concurrent arm and after the fourth cycle in the sequential arm. Results: The median progression-free survival time was 16.5 months (95% confidence interval [CI], 9.0 to 24.1 months) for the sequential arm, and 26.3 months (95% CI, 16.6 to 35.9 months) for the concurrent arm. The 2-year progression-free survival rate was 16.0 percent for the sequential arm and 50.0 percent for the concurrent arm (p=0.0950 by log-rank test). Leukopenia was more severe and more frequent in the concurrent arm than in the sequential arm. However, severe esophagitis was infrequent in both arms. The radiotherapy was interrupted more frequently in the concurrent arm than in the sequential arm due to hematologic toxicities (p=0.001). Conclusion: This study suggests that concurrent TRT with etoposide plus cisplatin is more effective for the treatment of LS-SCLC than sequential TRT. However, there is a significant increase in the risk of toxicities, and radiotherapy was frequently interrupted in the concurrent arm due to hematologic toxicities.
Keywords
Chemoradiotherapy; Limited-stage; Small-cell lung cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Pignon JP, Arriagada R, Ihde D, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624   DOI   PUBMED   ScienceOn
2 Cox DR. Regression models and life table. J R Stat Soc B 1972;34:181-220
3 Lee CG, Kim JH, Suh CO, et al. Randomized trial of early versus late alternative radiotherapy/chemotherapy in limiteddisease patients with small cell lung cancer. J Korean Soc Ther Radiol Oncol 2002;20:116-122
4 Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912-918   DOI   PUBMED   ScienceOn
5 Turrisi AT III, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271   DOI   ScienceOn
6 Komaki R, Byhardt RW, Anderson T, et al. What is the lowest effective biologic dose for prophylactic cranial irradiation? Am J Clin Oncol 1985;8:523-527   DOI   ScienceOn
7 Cox D, Snell E. Analysis of Binary Data. 2nd ed. London;Chapman & Hall, 1989
8 Perez CA, Einhorn L, Oldham RK, et al. Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. J Clin Oncol 1984;2:1200-1208   DOI   PUBMED
9 Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-3060   DOI   ScienceOn
10 Kim SH, Choi BO, Gil HJ, et al. The results of radiation therapy of limited stage small cell lung cancer. J Korean Soc Ther Radiol Oncol 1993;11:97-102
11 Peto R, Pike M. Conservatism of the approximation S (O-E)2/E in the log-rank test for survival data or tumour incidence data. Biometrics 1973;29:759-784
12 Murray N, Coy P, Pater JL, et al. The importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993;11:336-344   PUBMED
13 Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective, randomized trial. Ann Intern Med 1987;106:655-662   DOI   PUBMED   ScienceOn
14 Spiro SG, James LE, Rudd RM, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and met-analysis. J Clin Oncol 20060;24:3823-3830   DOI   ScienceOn
15 Sierocki JS, Hilaris BS, Hopfan S, et al. cis-Dichlorodiammineplatinum (II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 1979;63:1593-1597   PUBMED
16 World Health Organization. Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48). Geneva: World Health Organization, 1979
17 Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481   DOI   ScienceOn
18 Greco FA, Brereton HD, Kent H, et al. Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann Intern Med 1976;85:294-298   DOI   PUBMED   ScienceOn
19 Eagan RT, Ingle JN, Frytak S, et al. Platinum-based polychemotherapy versus dianhydrogalactitol in advanced nonsmall cell lung cancer. Cancer Treat Rep 1977;61:1339-1345   PUBMED
20 Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest 1997;112(Suppl. 4):S251-258   DOI
21 Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4837-4845   DOI   PUBMED   ScienceOn